What is the intrinsic value of TBPH?
As of 2025-09-18, the Intrinsic Value of Theravance Biopharma Inc (TBPH) is
6.47 USD. This TBPH valuation is based on the model Peter Lynch Fair Value.
With the current market price of 14.05 USD, the upside of Theravance Biopharma Inc is
-53.96%.
Is TBPH undervalued or overvalued?
Based on its market price of 14.05 USD and our intrinsic valuation, Theravance Biopharma Inc (TBPH) is overvalued by 53.96%.
TBPH Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(60.64) - (7.85) |
(16.36) |
-216.4% |
| DCF (Growth 10y) |
(7.77) - (53.59) |
(15.24) |
-208.5% |
| DCF (EBITDA 5y) |
(0.63) - (4.83) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(2.66) - (7.28) |
(1,234.50) |
-123450.0% |
| Fair Value |
6.47 - 6.47 |
6.47 |
-53.96% |
| P/E |
2.22 - 7.79 |
3.89 |
-72.3% |
| EV/EBITDA |
2.53 - 2.11 |
2.69 |
-80.9% |
| EPV |
(4.79) - (10.80) |
(7.80) |
-155.5% |
| DDM - Stable |
2.59 - 17.15 |
9.87 |
-29.8% |
| DDM - Multi |
(9.29) - (49.31) |
(15.79) |
-212.4% |
TBPH Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
707.56 |
| Beta |
1.11 |
| Outstanding shares (mil) |
50.36 |
| Enterprise Value (mil) |
400.39 |
| Market risk premium |
4.60% |
| Cost of Equity |
8.17% |
| Cost of Debt |
5.00% |
| WACC |
8.04% |